These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
488 related items for PubMed ID: 1617660
1. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR. Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660 [Abstract] [Full Text] [Related]
3. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Sharp SY, Rogers PM, Kelland LR. Clin Cancer Res; 1995 Sep 15; 1(9):981-9. PubMed ID: 9816070 [Abstract] [Full Text] [Related]
4. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR. Cancer Res; 1992 Nov 15; 52(22):6188-93. PubMed ID: 1423261 [Abstract] [Full Text] [Related]
7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR. Clin Cancer Res; 1997 Nov 15; 3(11):2063-74. PubMed ID: 9815598 [Abstract] [Full Text] [Related]
9. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). Yoshida M, Khokhar AR, Siddik ZH. Cancer Res; 1994 Sep 01; 54(17):4691-7. PubMed ID: 8062266 [Abstract] [Full Text] [Related]
10. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Br J Cancer; 1992 Dec 01; 66(6):1109-15. PubMed ID: 1457352 [Abstract] [Full Text] [Related]
11. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Cancer Res; 1992 Feb 15; 52(4):822-8. PubMed ID: 1737343 [Abstract] [Full Text] [Related]
12. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR. Cancer Res; 1992 Apr 01; 52(7):1710-6. PubMed ID: 1312897 [Abstract] [Full Text] [Related]
13. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Shellard SA, Hosking LK, Hill BT. Cancer Res; 1991 Sep 01; 51(17):4557-64. PubMed ID: 1873800 [Abstract] [Full Text] [Related]
14. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]. Mellish KJ, Barnard CF, Kelland LR, Harrap KR. Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906 [Abstract] [Full Text] [Related]
15. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Yoshida M, Khokhar AR, Siddik ZH. Cancer Res; 1994 Jul 01; 54(13):3468-73. PubMed ID: 8012968 [Abstract] [Full Text] [Related]
16. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Mellish KJ, Kelland LR, Harrap KR. Br J Cancer; 1993 Aug 01; 68(2):240-50. PubMed ID: 8347478 [Abstract] [Full Text] [Related]
17. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. McKeage MJ, Abel G, Kelland LR, Harrap KR. Br J Cancer; 1994 Jan 01; 69(1):1-7. PubMed ID: 8286188 [Abstract] [Full Text] [Related]
18. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Kasparkova J, Marini V, Najajreh Y, Gibson D, Brabec V. Biochemistry; 2003 May 27; 42(20):6321-32. PubMed ID: 12755637 [Abstract] [Full Text] [Related]
19. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. O'Neill CF, Hunakova L, Kelland LR. Chem Biol Interact; 1999 Nov 15; 123(1):11-29. PubMed ID: 10597899 [Abstract] [Full Text] [Related]
20. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Cancer Res; 1986 Apr 15; 46(4 Pt 2):1972-9. PubMed ID: 3512077 [Abstract] [Full Text] [Related] Page: [Next] [New Search]